Tatton Consulting supported Birmingham-based pharmaceutical formulation company Mesox in its successful application to VPAG – EOI, awarded £93,199 by Innovate UK for the project Digital Formulation Design and Manufacture for a Sustainable Pipeline of the Next-Generation of Bioavailable Medicines.
About the funded R&D project
Poor bioavailability affects 70-90% of pipeline drugs and 40% of marketed medicines, and contributes to an estimated 17% of Phase I trial failures. The project develops digital formulation design and manufacture, shifting work that currently consumes bench time and material into computation.
Award details
- Total project grant: £93,199
- Of which to Mesox: £49,522
- Competition: VPAG – EOI
- Competition year: 2024/25
- Project: Digital Formulation Design and Manufacture for a Sustainable Pipeline of the Next-Generation of Bioavailable Medicines
- Sector: Pharmaceutical manufacturing / digital design
- UKRI project record: Gateway to Research, project 10145660
- Dataset: Innovate UK funded projects, published 10 August 2026
Tatton Consulting supported the competitive grant application. The award value, competition and project title are taken from UKRI’s published record for this project.
See all Innovate UK awards Tatton Consulting has supported on our grant successes page.
